Seres Therapeutics Current Valuation vs. Shares Owned By Insiders
| 1S9 Stock | EUR 0.82 0.02 2.38% |
For Seres Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Seres Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Seres Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Seres Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Seres Therapeutics over time as well as its relative position and ranking within its peers.
Seres |
Seres Therapeutics Shares Owned By Insiders vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Seres Therapeutics's current stock value. Our valuation model uses many indicators to compare Seres Therapeutics value to that of its competitors to determine the firm's financial worth. Seres Therapeutics is the top company in current valuation category among its peers. It also is number one stock in shares owned by insiders category among its peers . The ratio of Current Valuation to Shares Owned By Insiders for Seres Therapeutics is about 87,505,931 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Seres Therapeutics' earnings, one of the primary drivers of an investment's value.Seres Current Valuation vs. Competition
Seres Therapeutics is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is presently estimated at about 79.31 Billion. Seres Therapeutics maintains roughly 582.79 Million in current valuation contributing less than 1% to stocks in Biotechnology industry.
Seres Shares Owned By Insiders vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Seres Therapeutics |
| = | 582.79 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Seres Therapeutics |
| = | 6.66 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Seres Shares Owned By Insiders Comparison
Seres Therapeutics is currently under evaluation in shares owned by insiders category among its peers.
Seres Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Seres Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Seres Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Seres Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Seres Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. SERES THERAPEUT operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 155 people.
Seres Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Seres Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Seres Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Seres Therapeutics' important profitability drivers and their relationship over time.
Use Seres Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Seres Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Seres Therapeutics will appreciate offsetting losses from the drop in the long position's value.Seres Therapeutics Pair Trading
Seres Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Seres Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Seres Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Seres Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Seres Therapeutics to buy it.
The correlation of Seres Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Seres Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Seres Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Seres Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Seres Therapeutics position
In addition to having Seres Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corona Opportunity Thematic Idea Now
Corona Opportunity
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Seres Stock
When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Trending Equities. For more detail on how to invest in Seres Stock please use our How to Invest in Seres Therapeutics guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
To fully project Seres Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Seres Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Seres Therapeutics' income statement, its balance sheet, and the statement of cash flows.